"Identifying new targets to boost immune responses to cancer is the first step toward safer and more effective antitumor drugs."
DR. PEDRO BERRAONDO LÓPEZ RESEARCHER. CYTOKINE-BASED THERAPEUTICS RESEARCH GROUP
The Cytokine-Based Therapies Research Group at Cima focuses on the study of cytokines, molecules that mediate communication between cells of the immune system.
The use of immunostimulatory monoclonal antibodies has revolutionized cancer treatment and to obtain the maximum potential of these new treatments it is necessary to develop drugs based on cytokines.
The aim of our group is to deepen the knowledge of these molecules and to design sophisticated strategies to improve their therapeutic properties, contributing to the development of safe and effective drugs.
Need more information?
If you are interested in learning more about our research, please contact us
Objectives of the Cytokine-Based Therapies Research Group
We seek to enhance immunotherapy treatments through cross-cutting research
In-depth knowledge of cytokine biology.
Identify new molecular targets and design innovative therapeutic strategies.
To develop new, safer and more effective antitumor drugs.
Cytokines in clinical cancer immunotherapy
The antitumor properties of cytokines have led to an exponential increase in the number of research and clinical trials exploring the safety and efficacy of cytokine-based drugs, not only as single agents but also in combination with other immunomodulatory drugs.
These new trends in the field of cytokine immunotherapy are producing promising therapeutic agents and the design of new strategies with potential clinical application, such as anti-TNF therapy.
Meet the research team
Scientific activity of the
Cytokine-Based Therapies Research Group
Latest scientific publications
- Revisiting intracavitary immunotherapy of cancer May 13, 2022 | Magazine: Clinical Cancer Research
- Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB 1 and CB 2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia Jan 12, 2022 | Magazine: Science Translational Medicine
- Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model Apr 13, 2021 | Magazine: Journal of Nanobiotechnology
- High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach Mar 5, 2021 | Magazine: Biomedicines